Navigation Links
Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
Date:3/26/2009

PRINCETON, N.J., March 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that Dr. Geoffrey M. Nichol, Senior Vice President of Product Development at Medarex presented highlights from key programs in Medarex's oncology portfolio at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference in New York. The archived edition of the presentation webcast is available in the Investor Relations section of the Medarex website at www.medarex.com.

Highlights from Medarex's oncology portfolio included the following:

  • Ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate cancer and other cancers. Guidance for the completion of the first-line Phase 3 chemotherapy combination trial in melanoma (study 024) remains unchanged and is expected in late 2009, with overall survival as the primary endpoint under the amended Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Initiation of the second-line Phase 3 radiotherapy combination trial in prostate cancer remains on track for mid-2009. Additional data, including survival and biomarker analyses from the melanoma Phase 2 program and data from the Phase 2 prostate program, will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in May/June.
  • MDX-1105 and MDX-1106 are two fully human antibodies that target the PD-L1/PD-1 pathway for the treatment of cancer. MDX-1105 is in an ongoing multi-dose Phase 1 trial for advanced or recurrent renal cancer, melanoma, non-small cell lung cancer or epithelial cancer. MDX-1106 is in an ongoing multi-dose Phase 1b trial for prostate cancer, melanoma, non-small cell lung cancer and renal cancer. Complete MDX-1106 Phase 1 data will
    '/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medarex Announces 2008 Fourth Quarter and Year End Financial Results
2. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. Medarex Reviews Recent Highlights and Outlook for 2009
5. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
6. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
7. Medarex Announces 2008 First Quarter Financial Results
8. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
9. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
10. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... a healthy weight. The study shows a higher body mass ... of life in older age. ,Since the beginning ... life expectancy. Meanwhile, the prevalence of overweight and obesity among ... an impact on individuals as they age? Researchers conducted a ...
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... because lifestyle changes and medication can prevent or delay the ... is used to identify high-risk individuals for diabetes, but the ... cluster of risk //factors known as metabolic syndrome is able ... ,Metabolic syndrome has been shown to lead to ...
... problem worldwide. Both osteoarthritis and rheumatoid arthritis cause joint ... for arthritis and no effective treatment to repair damaged ... doctors towards a drug to prevent the onset of ... enzyme that play a pivotal role in the onset ...
... New research finds that women who change partners between the births ... babies with a low birth weight than women who have the ... likely to die within the first year of life. The results ... age and education, the interval between births, and the decades of ...
... pain, the right mattress can make a difference. //Three-quarters of ... but a new study says they could be wrong. The ... back pain. ,Physicians often get frustrated when patients ... lower back pain. Few studies have been done on this ...
Cached Medicine News:Health News:Excess Weight Can Affect Individuals as They Age 2Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ... fat content and preserved lean body mass following ...
(Date:1/14/2014)... , Jan. 14, 2014 ... ), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced that it ... will be approximately $53 million, bringing expected full-year ... "Our full-year revenue growth of 87% for 2013 ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the ... the Miami Beach Convention Center ... More than 3,500 attendees from top ... part in the conference, which includes on-site education sessions, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Medicine Products: